Vera Therapeutics Inc
VERAHealthcare|Biotechnology|USA
$42.00
-0.45 (-1.06%)
Tangible Book
$6.97
Earnings Power
$7.21
About
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Stock Price
+72.5%(1Y)
Pipeline Summary
24 total trials0
Phase 1
8
Phase 2
3
Phase 3
2
Phase 4
Withdrawn: 2Recruiting: 3Active: 2Completed: 13ENROLLING_BY_INVITATION: 1Unknown: 2Terminated: 1
Active Trials (5)
Atacicept in Multiple Glomerular Diseases
NCT06983028pMN
Phase 2Recruiting
Enrollment: 250 participants
Atacicept in Subjects With IgA Nephropathy
NCT04716231IgA Nephropathy
Phase 3Active
Enrollment: 376 participants
Monthly Dosing of Atacicept in IgAN
NCT07020923IgA Nephropathy (IgAN)
Phase 2Active
Enrollment: 90 participants
Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis
NCT06958588Venous Thromboembolism (VTE)
Phase 4Recruiting
Enrollment: 50 participants
Effect of Virtual Reality Use on Preoperative Anxiety
NCT07270445Anxiety
N/ARecruiting
Enrollment: 172 participants
BioScore
4.7/10
Cautious
Ownership
Recent Insider Trades
Fordyce MarshallSELL
2026-07-0746,250 shares @ $42.3
Fordyce MarshallSELL
2026-06-2318,500 shares @ $37.93
Fordyce MarshallSELL
2026-05-1218,500 shares @ $36.74
Fordyce MarshallSELL
2026-04-1422,951 shares @ $44.05
Brenner RobertSELL
2026-02-232,151 shares @ $41.98
Recent News
2026-07-08 16:39:27
2026-07-08 16:01:13
2026-07-08 15:43:59
2026-07-08 14:50:33
2026-07-07 19:31:32
Data last updated: Jul 12, 2026, 07:38 PM